검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Bendamustine + Rituximab (Bendamustine + Rituximab) Roche / Genentech·Chronic Lymphocytic Leukemia ORR 95% |
|---|---|
Overview Program | Bendamustine + Rituximab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Marginal Zone Lymphoma(MZL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets the B-cell antigen |
MoA Biomarker | biomarker data at diagnosis were included in the survival analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.. We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety an… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 95% |
Clinical ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT02596971 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-8 · 마지막 7월 21일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Bendamustine + Rituximab (Bendamustine + Rituximab) Roche / Genentech·Chronic Lymphocytic Leukemia ORR 95% |
|---|---|
Overview Program | Bendamustine + Rituximab |
Overview Company | Roche / Genentech |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukemia |
Overview Indication | Marginal Zone Lymphoma(MZL) |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Mechanism | targets the B-cell antigen |
MoA Biomarker | biomarker data at diagnosis were included in the survival analysis |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Bendamustine/Rituximab Induction Followed by Venetoclax/Rituximab Consolidation in Frontline Treatment of Chronic Lymphocytic Leukemia: A Phase 2 Multi-Center Study.. We hypothesized that a time-limited frontline treatment strategy with abbreviated chemoimmunotherapy followed by targeted consolidation could achieve durable disease control with manageable toxicity in CLL. We evaluated the safety an… |
Toxicology CRS | Reported |
Clinical Primary efficacy | ORR 95% |
Clinical ORR | 95.0% |
Clinical Result source | ClinicalTrials.gov NCT02596971 |
Clinical Data Tier / Score | A · 62 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 18일 (8일 전) |
추천 비교
추천 비교